Out-Licensing (OL)

Polpharma’s services include EU standard dossiers for finished dosage formulations based on active pharmaceutical ingredients (API) developed in-house or outsourced. The company’s out-licensing (OL) portfolio secures the most comprehensive offer for its clients.

Co-operation with Polpharma can bring you several advantages, including:

  • New products developed in three research and development (R&D) centers
  • Very large portfolio to offer comprehensive dossiers
  • Ten products in development and 20 products in early stage of development
  • New products predominantly based on internally manufactured API
  • Attractive products such as first generics, modern combo products and ophthalmic products without preservatives
  • Dossiers meeting European guidelines adapted to local non-EU requirements
  • Comprehensive manufacturing experience focused on lowering production cost
  • Continuous out-licensing activity of our generic products with favourable conditions for our clients

More About This Company